The metastasis-promoting protein TWIST1 contains a highly immunogenic peptide sequence (TWIST1₁₄₀₋₁₆₂) that activates cancer-fighting T-cells, with stronger responses in breast cancer patients than healthy donors.
Stronger responses in cancer patientsBreast cancer patients showed greater TWIST1-specific CD4+ T-cell activation than healthy donors, indicating natural immune recognition of this shared tumor antigen
What the researchers found
The researchers identified TWIST1₁₄₀₋₁₆₂ as an immunogenic peptide sequence within the TWIST1 protein that effectively activated TWIST1-specific CD4+ helper T-cells. Key findings:
- Breast cancer patients showed stronger TWIST1-specific immune responses in short-term culture assays compared to healthy donors, indicating pre-existing immune recognition
- Vaccination with the TWIST1 peptide in humanized mice efficiently expanded TWIST1-reactive helper T-lymphocytes
- TWIST1 is upregulated in tumor cells under hypoxia and promotes metastasis — it appears late in tumor progression when the immune-suppressive microenvironment allows its expression despite its immunogenicity
The study's hypothesis — that highly immunogenic molecules can be expressed by tumors only after establishing immune suppression — provides a rational framework for identifying shared cancer vaccine targets.
Why it matters
Most cancer vaccine approaches require identifying unique mutations in each patient's tumor — an expensive and time-consuming process. TWIST1 is a shared antigen expressed across many patients' tumors, meaning a single vaccine could work for many people. Because TWIST1 drives metastasis (the main cause of cancer death), targeting it immunologically could both treat existing disease and prevent cancer spread.
How the study worked
TWIST1 peptide sequences were analyzed for immunogenicity. The peptide TWIST1₁₄₀₋₁₆₂ was tested for its ability to activate CD4+ T-cells. T-cell responses were compared between breast cancer patients and healthy donors using short-term culture assays. In vivo vaccination was tested in humanized mice (mice engrafted with human immune systems) to assess TWIST1-reactive helper T-lymphocyte expansion.
What this study cannot tell us
The study focused primarily on breast cancer patients, so TWIST1 immunogenicity in other cancer types needs confirmation. The humanized mouse model, while valuable, does not fully replicate the human immune system. Long-term vaccination efficacy and actual tumor rejection were not demonstrated. The correlation between TWIST1-specific T-cell responses and clinical outcomes was not assessed. Sample sizes for patient comparisons were not specified.
How to read the evidence
This is a preclinical/translational study combining human patient immune analysis with humanized mouse vaccination. It demonstrates immunogenicity and T-cell activation but does not yet show therapeutic tumor rejection or clinical benefit.
When this study was published
Published in 2022 in Cancer Science, this study represents a recent advance in identifying shared cancer antigens for peptide vaccine development.
The bigger picture
This study introduces an elegant concept based on cancer immunoediting theory: immunogenic proteins that help tumors survive (like TWIST1 promoting metastasis) can only be expressed after the tumor creates an immune-suppressive environment. This means these proteins are simultaneously important for the tumor AND recognizable by the immune system — making them ideal vaccine targets. This framework could guide discovery of other shared cancer antigens beyond TWIST1.
Questions still open
- Can a TWIST1 peptide vaccine induce actual tumor rejection and prevent metastasis in advanced cancer models?
- Is TWIST1 immunogenic across other cancer types that commonly metastasize (lung, colorectal, pancreatic)?
- Could combining the TWIST1 peptide vaccine with checkpoint inhibitors enhance anti-tumor immune responses?
Common questions
Why is TWIST1 a good cancer vaccine target?
How is a peptide vaccine different from other cancer treatments?
Read the original research
A tumor metastasis-associated molecule TWIST1 is a favorable target for cancer immunotherapy due to its immunogenicity.
Cancer science, 113(8), 2526-2535
Citation
Yajima, Yuki; Kosaka, Akemi; Ishibashi, Kei; Yasuda, Shunsuke; Komatsuda, Hiroki; Nagato, Toshihiro; Oikawa, Kensuke; Kitada, Masahiro; Takekawa, Masanori; Kumai, Takumi; Ohara, Kenzo; Ohkuri, Takayuki; Kobayashi, Hiroya. (2022). A tumor metastasis-associated molecule TWIST1 is a favorable target for cancer immunotherapy due to its immunogenicity.. Cancer science, 113(8), 2526-2535. https://doi.org/10.1111/cas.15429